ArticleIn vitro cellular & developmental biology. Animal2025
Maxing Yigan formula promotes cartilage regeneration by regulating chondrocyte autophagy in osteoarthritis.
Article in In vitro cellular & developmental biology. Animal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Maxing Yigan formula (MYF) is a traditional Chinese medicine (TCM) prescription used for the treatment of OA for decades in China. However, the mechanism remains unknown. In this study, we developed a MYF-incorporated collagen sponge (MYF@CS) and investigated its cartilage regeneration effect and the underlying mechanism. In vitro experiments revealed that MYF significantly promoted cell viability, proliferation, and autophagy of OA chondrocytes. Furthermore, MYF@CS significantly enhanced chondrogenesis and cartilage regeneration, as assessed by macroscopic observation, the International Cartilage Repair Society (ICRS) visual histological score, and histological examination. Our findings suggest that MYF@CS could represent a significant therapeutic strategy for the treatment of OA.
Indexed as
Identifiers
39718676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.